Reproducibility of Echocardiographic Techniques for Sequential Assessment of Left Ventricular Ejection Fraction and Volumes Application to Patients Undergoing Cancer Chemotherapy by Thavendiranathan, Paaladinesh et al.
t
L
i
Journal of the American College of Cardiology Vol. 61, No. 1, 2013
© 2013 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00Cardiac Imaging
Reproducibility of Echocardiographic
Techniques for Sequential Assessment of
Left Ventricular Ejection Fraction and Volumes
Application to Patients Undergoing Cancer Chemotherapy
Paaladinesh Thavendiranathan, MD, MSC, Andrew D. Grant, MD, Tomoko Negishi, MD,
Juan Carlos Plana, MD, Zoran B. Popovic´, MD, PHD, Thomas H. Marwick, MD, PHD, MPH
Cleveland, Ohio
Objectives The aim of this study was to identify the best echocardiographic method for sequential quantification of left ven-
tricular (LV) ejection fraction (EF) and volumes in patients undergoing cancer chemotherapy.
Background Decisions regarding cancer therapy are based on temporal changes of EF. However the method for EF measure-
ment with the lowest temporal variability is unknown.
Methods We selected patients in whom stable function in the face of chemotherapy for breast cancer was defined by sta-
bility of global longitudinal strain (GLS) at up to 5 time points (baseline, 3, 6, 9, and 12 months). In this way,
changes in EF were considered to reflect temporal variability of measurements rather than cardiotoxicity. A com-
prehensive echocardiogram consisting of 2-dimensional (2D) and 3-dimensional (3D) acquisitions with and with-
out contrast administration was performed at each time point. Stable LV function was defined as normal GLS
(16.0%) at each examination. The EF and volumes were measured with 2D-biplane Simpson’s method, 2D-
triplane, and 3-dimensional echocardiography (3DE) by 2 investigators blinded to any clinical data. Inter-, intra-,
and test-retest variability were assessed in a subgroup. Variability was assessed by analysis of variance and
compared with Levene’s or t test.
Results Among 56 patients (all female, 54  13 years of age), noncontrast 3D EF, end-diastolic volume, and end-
systolic volume had significantly lower temporal variability than all other methods. Contrast only decreased the
temporal variability of LV end-diastolic volume measurements by the 2D biplane method. Our data suggest that
a temporal variability in EF of 0.06 might occur with noncontrast 3DE due to physiological differences and mea-
surement variability, whereas this might be 0.10 with 2D methods. Overall, 3DE also had the best intra- and
inter-observer as well as test-retest variability.
Conclusions Noncontrast 3DE was the most reproducible technique for LVEF and LV volume measurements over 1 year of
follow-up. (J Am Coll Cardiol 2013;61:77–84) © 2013 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.09.035Sequential measurement of ejection fraction (EF) is used in
a variety of conditions, perhaps most commonly in the
assessment of potential cardiotoxicity from chemotherapy or
immune therapy in patients with malignancies (1). Cardio-
toxicity is most commonly defined as a reduction of the
left ventricular (LV) EF of 5% to 55% with symp-
oms of heart failure or an asymptomatic reduction of the
VEF of 10% to 55% (2). Because decisions regard-
ng cessation of lifesaving therapy (3) are based on
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accepted September 4, 2012.changes in EF values (4,5), it is important that EF
measurement should not only be accurate but also have
the lowest temporal variability such that a change in EF
truly represents cardiotoxicity.
See page 85
Echocardiography remains the most common modality
for EF measurements, but the method for EF measurement
with the lowest temporal variability is unknown. Although
3-dimensional echocardiography (3DE) has been shown to
be more accurate than 2-dimensional echocardiography
(2DE) for both ventricular volume and EF measurements
when compared with cardiac magnetic resonance imaging
(6,7), no head-to-head comparison of 3DE with 2D meth-
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available. Also, because 3DE ac-
quisition and post-processing are
still not routine, 2D methods in-
cluding the biplane (2DBi) and
triplane (2DTri) Simpson’s meth-
ods are more commonly used in
routine echocardiography. We
sought to identify which of the
commonly used echocardiographic
techniques had the lowest tempo-
ral variability for EF and ventricu-
lar volumes, on the basis of multi-
ple echocardiograms done over 1
year in women with breast cancer
receiving chemotherapy who were
clinically stable and had normal
global longitudinal strain at each
visit. The quantification methods
compared include: 1) 2DBi; 2)
2DTri; and 3) 3D full volume ac-
quisition. All methods were com-
pared with and without LV opacifi-
cation with contrast agents.
Methods
Patient selection. All patients referred to our echocardi-
ography laboratory for LV function assessment before or
during chemotherapy were prospectively enrolled in a data-
base approved by the Institutional Review Board from
between May 2010 and October 2011. We selected patients
in whom stable function in the face of chemotherapy for
breast cancer was defined by stability of global longitudinal
strain (GLS) at up to 5 time points (baseline, 3, 6, 9, and 12
months). In this way, changes in EF were considered to
reflect temporal variability of measurements rather than
cardiotoxicity.
Inclusion criteria consisted of having had: 1) all echocar-
diography studies performed with Vivid 7 or E9 (GE
Healthcare, Milwaukee, Wisconsin) ultrasound systems;
2) images for EF quantification along with high frame rate
2D acquisitions for speckle strain analysis at every follow-
up; and 3) normal 2D systolic average global systolic
longitudinal strain (GLS) at every follow-up study (defined
as GLS 16%). Exclusion criteria consisted of: 1) a
GLS value of 16% at any time point; 2) baseline or
interval diagnosis of coronary artery disease, other
nonchemotherapy-induced cardiomyopathy, or more
than moderate mitral or aortic regurgitation; 3) clinical
diagnosis of heart failure during follow-up; and 4) initi-
ation of cardiac medications such as beta-blockers during
the follow-up period.
LV function by 2DE and 3DE. As part of the chemo-
therapy protocol, all patients receive a complete echocardio-
Abbreviations
and Acronyms
2DBi  2-dimensional
biplane
2DE  2-dimensional
echocardiography
2DTri  2-dimensional
triplane
3DE  3-dimensional
echocardiography
CI  confidence interval
COV  coefficient of
variation
EDV  end-diastolic volume
EF  ejection fraction
ESV  end-systolic volume
GLS  average systolic
global longitudinal strain
LV  left ventricle/
ventricular
SEM  standard error of
measurementgram with and without contrast administration and myo-cardial strain assessment. Apical 2- and 4-chamber and
triplane acquisitions were obtained in each patient with
optimization of image quality during acquisition. A 3D full
volume dataset of the ventricle was obtained with gated (4
beats) acquisition with sector size, depth, and the number of
heart beats optimized to obtain the highest possible volume
rates. All acquisitions were then repeated after boluses of
contrast administration (Definity, Bristol-Myers Squibb
Medical Imaging, New York, New York, or Optison, GE
Healthcare) with the mechanical index adjusted to between
0.15 and 0.3 and image settings optimized (8). All 2D
post-contrast acquisitions were performed before 3D post-
contrast acquisitions.
The LV volumes and EF were measured offline with
EchoPAC (GE Healthcare) for all acquisitions except 3D
with contrast where Tomtec (4D LV-Function 2.2.14.7,
Unterschleissheim, Germany) analysis package was used.
The 2DBi measurements were performed by manual con-
touring of the 4- and 2-chamber views, whereas 2DTri
measurements required manual contouring of 3 long-axis
views of the LV. The 3D noncontrast EF was measured
with a semi-automated technique. Basal and apical guide
points were placed in 1 long-axis image in the end-diastolic
and end-systolic frames. Endocardial contours were then
automatically generated and displayed on multiple long- and
short-axis cine images for verification and manual adjustment
as necessary. For the 3D EF with contrast, 3 long-axis
images were manually contoured in end-diastole and end-
systole. The contouring was then verified on long- and
short-axis cine images and modified as necessary to ensure
optimal endocardial tracking. The EF and volume measure-
ments for each time point were measured blinded to the
prior measurement.
LV systolic average GLS. Apical 3-, 2-, and 4-chamber
high frame rate grayscale acquisitions (40 to 80 frames/s)
were obtained with commercially available equipment
(Vivid 7 or E9, GE Healthcare). Measurement of GLS was
performed as part of the routine clinical study on the
ultrasound system or offline with EchoPAC (GE Health-
care) and verified by a physician. GLS was measured for 3-,
2-, and 4-chamber views separately, and all 18 myocardial
segments were averaged to obtain the GLS. Segments that
were inadequately tracked were excluded from the analysis.
Our strain cutoff 16% was based on calculation of approx-
imately 2SD from the mean on the basis of known normal
strain values from a previous publication (9).
Reproducibility analysis. Interobserver and intraobserver
reproducibility and interobserver test-retest variability of the
EF and volume measurements for all 6 methods were tested
by 2 observers (P.T., A.G.) for 10 patients at 2 different
time points (baseline and 3 months). Before performing
these analyses the 2 observers first agreed on the method of
contouring for all 6 methods (contrast and noncontrast
studies) and practiced on 5 separate cases together. Each
observer measured each study twice with each measurement
performed at 2 separate time periods (2 to 4 weeks apart) in
1
w
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between time points. For interobserver and intraobserver
variability a total of 20 studies (10 from baseline, and 10
from follow-up) were used. For the interobserver test-retest
variability, measurement 1 and 2 for each patient by
observer 1 was compared with measurements 1 and 2 at
time point 2 by the second observer. The interobserver
test-retest variability provides an estimate of the expected
variability in EF and volumes in an echocardiography lab
where the measurements might be performed by 2 different
sonographers/physicians at different time points during the
follow-up period. All measurements were made by each
observer blinded to previous measurements and to the
measurements of the other observer.
Statistical analysis. Continuous data are expressed as mean
SD, whereas categorical data are expressed as frequency or
percentage. All absolute changes in EF values are represented
as decimals (e.g., 10% absolute EF change is represented as
0.10), whereas any relative change in EF is represented as a
percentage. Echocardiograms were categorized into 1 of 5
time periods: 1) before initiation of therapy or the first
available study; 2) 2 to 3 months; 3) 3 to  6 months;
4) 6 to 9 months; and 5) 9 to 12 months after initiation
of therapy or the first echocardiogram. All EF, volume, and
strain measurements were normally distributed as deter-
mined by the Kolmogorov-Smirnov test. To assess whether
there was a significant temporal variability in GLS in our
population, we used Linear Mixed Model analysis with
unstructured covariance for random effects (10) with strain
as a dependent variable, patients as random effect, and time
(in days) as a covariate. One-way analysis of variance
(ANOVA) was performed to obtain the mean squared error
for each technique studied. The square root provided the
standard error of the measurement (SEM) in the EF and
volume measurements for each method over the measure-
ment period. The 95% confidence interval (CI) for each
SEM was calculated with the formula:
(n 1)S2
U
2  
2 
(n 1)S2
L
2
where XU
2 is the upper-tail value of chi-square for df n
with area /2 to its right and XL
2 is the lower-tail value
ith area /2 to its left. In addition to the SEM the
coefficient of variation (COV) and 95% CI (calculated as
described in the preceding text) for the temporal variability
for each method was also calculated. Levene’s test was used
to test for differences in the SEM and COV between the
techniques. Because 5 comparisons of SEM and COV were
made (3D noncontrast technique vs. others) Bonferroni
correction was used with p  0.01 considered to be
statistically significant. The minimal change in EF or
volumes over time beyond which 2 measurements could be
considered to be different was calculated as 2 the SEM for
any technique.Intraobserver and interobserver variability were deter-
mined with 2-way ANOVA approach described by Eliasziw
et al. (11) with observers treated as random factors. With
this method the interobserver variability includes both the
variability among measurements of observers and the vari-
ability within measurements of observers (11). In addition,
the interobserver test-retest variation was also calculated
with 2-way ANOVA. This measure consists of variability
within observers, among observers, and over time. For these
3 measurements, with the formula in the following text, the
95% CI was calculated as a measure of the minimal
difference between 2 measurements beyond which the
measures can be considered to be truly different (11–13).
EFintra	 z
2
MSEintra
EFintra	 z
2
MSEinter
The differences in the calculated observer variability were
compared with the t test described by Tong et al (13).
Because 5 comparisons were made (3D noncontrast vs.
others) Bonferroni correction was used with a p  0.01
considered to be statistically significant. All statistical anal-
ysis was performed with SPSS (version 19.0.0, SPSS,
Chicago, Illinois).
Results
Patient population. A total of 88 patients with at least 3
echocardiograms were screened; 32 were excluded due to at
least 1 abnormal strain value during follow-up (16%) or
development of other reasons for LV dysfunction (e.g.,
coronary artery disease and viral myocarditis) or initiation of
beta-blockers during the follow-up period. Demographic
data of the 56 included patients and cancer therapy received
are summarized in Table 1. Patient follow-up ranged from
a total of 3 visits 3 months apart to as many as 5 visits
(baseline, 3, 6, 9, and 12 months).
Systolic GLS. The GLS values at each follow-up period
are summarized in Table 1. A total of 39 of 4,248 segments
(1.0%) were not used in the strain calculation due to poor
myocardial tracking. The average GLS for all patients and
all time points was19.6 2.0% and ranged from16.0%
to 24.9%. There was no significant temporal variability in
strain comparing all patients for all available time points
(p  0.79).
Temporal variability of EF. The EF measurements were
performed on 236 echocardiographic studies. However, due
to occasional refusal of contrast agent, missed acquisition of
1 or more methods of EF assessment in some studies, or
poor image quality, we were able to perform the following
number of measurements: 235 2DBi, 186 2DBi with
contrast, 225 2DTri, 177 2DTri with contrast, 215 3D, and
174 3D with contrast. The median (95% CI) frame/volume
rates for 2DBi, 2DBi with contrast, 2DTri, 2DTri with
contrast, 3D, and 3D with contrast were 74 (71 to 74),
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30 (26 to 33), respectively. The EF by each technique for
the entire follow-up period for all patients is shown in
Figure 1, whereas the mean SD values for each follow-up
time point are illustrated in Figure 2.
The temporal variability in EF measurements of each
technique is illustrated in Figure 3, with numerical SEM
and 95% CI values shown in the lower panel in Figure 3.
Among the techniques, noncontrast 3DE had the lowest
temporal variability compared with all the other EF meth-
ods. Contrast increased the temporal variability for 2DBi
(p  0.02), 2DTri (p  0.17), and 3D (p  0.001).
However, among the 3 contrast-enhanced methods, 3D had
the lowest temporal variability although only significantly
different in comparison with the contrast 2DTri technique
(p 0.001) and a trend toward improvement in comparison
with the 2DBi technique (p  0.09). The temporal vari-
Patient Demographic Data (N  56)Table 1 Patient Demographic Data (N  56)
Age, yrs 54 13
Diabetic 6 (11)
HTN 17 (30)
Smoker 19 (34)
Hyperlipidemia 15 (27)
Chemotherapy type
TCH 28 (50)
ACT  trastuzumab 15 (27)
Other 13 (23)
Mastectomy 52 (93)
Chest radiation 32 (57)
Strain, %
Baseline (n  56) 19.6 1.8
3 months (n  56) 19.6 2.0
6 months (n  56) 19.4 2.1
9 months (n  45) 19.5 2.0
12 months (n  23) 19.9 2.3
Values are mean  SD or n (%).
ACT  adriamycin, cyclophosphamide, and paclitaxel  trastuzumab; HTN  hypertension;
Other  various combinations including trastuzumab; TCH  Taxotere, Carboplatin, Herceptin
(Trastuzumab).
Figure 1 Mean EF and Volumes for Entire Follow-Up Period
For each method compared, the mean ejection fraction (EF), end-diastolic volume
illustrated. Error bars illustrate 1 SD. 3D  3-dimensional; Bi  biplane; Co  conability of EF measurements for each method is provided as
COV in Online Table A.
Temporal variability of LV volume. The end-diastolic
volume (EDV) and end-systolic volume (ESV) measure-
ments by each technique for the entire follow-up period are
illustrated in Figure 1, and the mean values at each time
point are illustrated in Figure 2. The temporal variability in
EDV and ESV for each technique is illustrated in Figure 4,
with numerical SEM and 95% CI values shown in the lower
panel in Figure 4. Noncontrast 3DE had the lowest temporal
variability for both EDV and ESV and was significantly lower
than all the other methods compared. Administration of
contrast agents decreased the temporal variability in EDV
measurements for the 2DBi method (p  0.02) but in-
creased it for the 3D method (p  0.001). Contrast did not
improve the ESV measurements for any of the techniques.
Among the contrast-enhanced techniques when the 3D
method was compared with the other 2 methods, there was
no difference in the temporal variability for both EDV (p 
0.12 vs. 2DBi, p  0.19 vs. 2DTri) and ESV (p  0.20 vs.
2DBi, p  0.31 vs. 2DTri). The temporal variability of
volume measurements for each method is provided as COV
in Online Table A.
Interobserver and intraobserver variability. The interob-
server and intraobserver variability for all 6 methods ex-
pressed as SEM and 95% CI for both EF and volumes are
summarized in Tables 2 and 3. For EF measurements,
noncontrast 3DE had the lowest intraobserver and interob-
server variability with minimal detectable change in EF of
0.048 and 0.075, respectively. Among the contrast-
enhanced techniques 3DE had the lowest interobserver and
intraobserver variability. For EDV and ESV the intraob-
server variability was the lowest for the noncontrast 3D
technique, with minimal detectable change of 14.3 and 8.1
ml, respectively. For interobserver variability, the 2DBi with
contrast method showed marginally smaller variability com-
pared with noncontrast 3D. For both the 2DBi and 2DTri
techniques, contrast decreased the interobserver and intrao-
and end-systolic volume (ESV) for all patients at all available time points are
Tri  triplane.(EDV),
trast;
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technique.
Test-retest variability. The overall interobserver test-
retest variability for EF and volumes for each method is also
summarized in Tables 2 and 3, respectively. For EF and
ESV measurements, noncontrast 3DE had the lowest vari-
ability, with minimal detectable EF and ESV differences of
0.060 and 14 ml, respectively. For EDV measurement, 3D
with contrast had the lowest variability followed by 3D
Figure 2 Mean EF and Volumes for Each Time Point
For each method compared, the EF, EDV, and ESV at each time point is the mean
Error bars illustrate 1 SD. Abbreviations as in Figure 1.
Figure 3 Temporal Variability in EF
The temporal variability is defined as the standard error of measurement (SEM)
and 95% confidence intervals (CIs) for each technique for the entire follow-up
period. Noncontrast 3D had the lowest temporal variability and 95% CI for EF
measurements (lower panel) compared with all methods (p  0.01 for all com-
parisons against noncontrast 3D). *p  0.05 for comparison of contrast
enhanced to noncontrast acquisition for the respective technique. Abbrevia-
tions as in Figure 1.without contrast. The minimal detectable changes for EDV
with these methods were 30.1 and 34.8 ml, respectively.
Discussion
This study provides a comparison of temporal and observer
variability in EF and volume measurements with commonly
used echocardiographic methods in patients with stable
ventricular systolic function undergoing chemotherapy for
Figure 4 Temporal Variability in EDV and ESV
Temporal variability is defined as the SEM and 95% CIs for each technique for
the entire follow-up period. Noncontrast 3D had the lowest temporal variability
and 95% CI for EDV and ESV measurements (lower panel) compared with all
methods (p  0.01 for all comparisons against noncontrast 3D). *p  0.05
for comparison of contrast enhanced to noncontrast acquisition for the respec-
tive technique. Abbreviations as in Figures 1 and 3.
l patients with available data at that time point.for al
triplan
c
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estimate of the minimal change in EF and volumes above
which 2 measurements should be considered to significantly
differ in excess of temporal and observer variability. Non-
contrast 3DE was most consistently superior for temporal
and observer variability for both EF and volume measure-
ments. Contrast administration did not improve variability
in measurements of EF or volumes in this population. Our
data indicate that a change in EF as high as 0.05 to 0.06 can
be seen over time with noncontrast 3D EF, due physiolog-
ical changes, acquisition differences, and observer variability.
In comparison this variability can be close to 0.10 to 0.13
with 2D techniques.
Sequential follow-up by echocardiography. In patients
with cancer, multiple studies are repeated during chemo-
therapy to monitor changes in EF as a marker of cardio-
toxicity, and this and other indications for repeat testing are
considered appropriate practice (14). However, the wide
CIs with 2DE reported in previous studies raises concern
about erroneously stopping chemotherapy due to changes in
EF that occur only due to variability on repeat testing.
Indeed, the utility of 2DE for sequential follow-up of
patients for LV volumes and function has been disappoint-
ing, with 11% being the smallest change in EF that can be
recognized with 95% confidence (15). A significant propor-
tion of this variability has been attributed to test-retest
variability (15).
The recommendation to perform sequential echocardio-
grams in these patients would be strengthened if measures
of LV function were sufficiently robust to more faithfully
Interobserver and Intraobserver Variability and Minimal DetectableTable 2 Interobserver and Intraobserver Variability and Minima
Bi Bi  Co
Intraobserver 0.033* 0.035*
Min  detectable 0.090 0.098
Interobserver 0.040 0.051*
Min  detectable 0.111 0.142
Interobserver test-retest 0.047* 0.055*
Min  detectable 0.013 0.152
Noncontrast 3D had the lowest intraobserver and interobserver test-retest observer variability and
0.01 t test compared with noncontrast 3D.
Bi  biplane Simpson’s; BP  Co  biplane Simpson’s with contrast; Tri  triplane; Tri  Co 
Interobserver and Intraobserver Variability for EDV and ESV MeasuAll 6 TechniquesTable 3 Interobserver and Intraobserver Variability for EDV ndAll 6 Techniques
Bi Bi  Co
EDV ESV EDV ESV EDV
Intraobserver 8.4 5.3* 6.5 3.7 7.8
Min  detectable 23.2 14.7 18.0 10.4 21.5
Interobserver 16.5† 7.4* 8.7 4.1 15.1†
Min  detectable 45.7 22.9 24.2 11.4 41.9
Test re-test 21.4† 10.3 13.8 6.9 13.8
Min  detectable 59.3 28.8 37.6 19.2 38.3
Interobserver and intraobserver variability for end-diastolic volume (EDV) and end-systolic volum
ompared with noncontrast 3D ESV; †p  0.01 t test compared with noncontrast 3D EDV.
Abbreviations as in Table 2.reflect variations in physiological differences between the
repeated studies. Cross-sectional studies have shown 3DE
to have less variation between studies than 2DE in com-
parison with magnetic resonance imaging (6,7). Only 1
study has illustrated more reproducible LV measurements
with 3DE on temporal follow-up on the basis of 2 time
points in patients with coronary artery disease (16). To
our knowledge, this is the first study to compare 2D and
3D methods with and without contrast administration in
a longitudinal study with multiple repeated echocardio-
grams to determine the method with the lowest temporal
variability.
In this study, controlling for nonphysiological changes in
EF and volumes with strain and clinical parameters, non-
contrast 3DE was superior to 2DE methods and contrast
3DE with respect to temporal variability in EF and vol-
umes. The superiority compared with 2DE methods is a
reflection that 3DE does not make any geometric assump-
tions for EF and volume measurements and is less affected
by acquisition differences from 1 scan to the next, as often
seen with 2DE (7,17). In addition noncontrast 3DE vol-
umes and EF were measured with a semi-automated
method where automatically generated contours are only
modified if necessary. This is in contrast to manual endo-
cardial contouring in all other methods where there can be
significant differences in the interpretation of endocardial
borders. The improved reproducibility of semi-automated
versus manual contouring has been previously illustrated by
others both with 2DE and 3DE (18,19). Specifically, this
latter reason likely accounts for the higher variability of
ge for EF Measurements by All 6 Techniquesectable Change for EF Measurements by All 6 Techniques
Tri Tri  Co 3D 3D  Co
0.038* 0.037* 0.017 0.026
0.104 0.102 0.048 0.072
0.049* 0.048* 0.027 0.038
0.135 0.133 0.075 0.100
0.058* 0.069* 0.022 0.042*
0.162 0.192 0.060 0.115
allest minimal detectable change. An ejection fraction (EF) of 0.033 corresponds to 3.3%. *p 
e  contrast; 3D  3-dimensional; 3D  Co  3-dimensional with contrast.
ts and Minimal Detectable Change byMe surements and Minimal Detectable Change by
Tri  Co 3D 3D  Co
ESV EDV ESV EDV ESV EDV ESV
3.8 5.7 3.8 5.1 2.9 6.1 4.7
10.5 15.9 10.4 14.3 8.1 16.8 13.0
9.2* 10.2 5.2 9.0 4.4 10.0 4.9
25.4 28.3 14.5 25.0 12.2 27.6 13.5
8.7 12.6 6.9 12.6 5.0 10.9 6.9
24.1 35.0 19.0 34.8 13.9 30.1 19.1
measurements (ml) and minimal detectable change (ml) by all 6 techniques. *p  0.01 t testChanl Det
the smremenESV
Tri
e (ESV)
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study. Additional reasons for lack of improvement with
contrast 3DE include lower volume rates of acquisitions
(i.e., 30 vs. 38 VPS) as well as limitations of the software
used for contrast 3DE analysis with respect to freedom in
endocardial contour adjustment.
Contrast administration has been shown to improve
accuracy and observer reproducibility with 2DE in patients
with sub-optimal echocardiographic windows (20,21).
However, other studies have shown the lack of additional
benefit over harmonic imaging with only limited improve-
ment or even worsening in reproducibility of EF measure-
ments in some patient populations (22–24). The latter
might be attributed to blooming and attenuation artifacts
that hinder delineation of structures such as the mitral valve,
resulting in variability in contouring (23). With 3DE,
previous work suggested improved accuracy with contrast
administration, even with good quality images (7). How-
ever, the lack of improvement in temporal variability in EF
or volume measurements with contrast administration ex-
cept for 2DBi EDV likely reflects the population studied.
With harmonic imaging most of our patients had adequate
acoustic windows and would not have met traditional
criteria for contrast administration. This is also supported by
the fact that we were able to analyze 235/236 2D images for
2DBi EF calculations. Unfortunately we were unable to
identify a subgroup of patients in our study cohort who had
at least 3 consecutive studies that would meet criteria for
contrast administration to perform a subgroup analysis.
In our study, the 2DTri method did not perform better
than the 2DBi method, for several reasons. The triplane
method was more susceptible to off-axis views of the
ventricle due to the difficulty in optimizing 3 separate views
in a single acquisition. Second, the endocardial border
delineation of the triplane images was inferior to the 2D
images used for biplane calculations. Also, the frame rates
for the triplane acquisition (47/s) were significantly lower
than those of 2D images used for biplane measurements
(74/s).
Interobserver and intraobserver variability. Previous
studies have also shown 3DE to have lower interobserver
and intraobserver variability probability, due to some of the
factors discussed in the preceding text (6,16). Our findings
are congruent with these studies. Another important vari-
ability is that seen between 2 studies at different time points
with measurements performed by different individuals (in-
terobserver test-retest variability). This is of direct clinical
importance, because patients are likely imaged by different
sonographers at different time points and the post-
processing is performed by different individuals. In this
study 3DE had the lowest interobserver test-retest variabil-
ity with minimal detectable difference in EF of 0.060. This
was significantly higher for the 2D techniques.
Study limitations. The average systolic GLS and clinical
criteria were used as a marker of stability of ventricular
function in these patients. Although, 2D speckle tracking-based strain measurement has limitations, the usefulness of
strain measurements as a marker of subclinical ventricular
dysfunction has been illustrated in several studies (25),
including in patients receiving chemotherapy (26,27). Al-
ternative study designs, including using sequential reference
measurements with cardiac magnetic resonance, were con-
sidered less feasible.
We were unable to obtain contrast enhanced images and
all 6 EF measurement methods of all patients at all time
points. This was due to the refusal of some patients to have
IV access or the inability to obtain IV access during
echocardiography or patient discomfort necessitating selec-
tive image acquisition. Likewise, although our data are
based on a small patient population, the critical variable is
the total number of echocardiographic studies.
All our EF and volume acquisitions and post-processing
were performed with specific vendor equipment and soft-
ware. Therefore our findings cannot be directly extrapolated
to other 3D acquisition and post-processing methods.
However, we do not feel that the longitudinal reproducibil-
ity data are reflective of a single vendor but rather the
semi-automated 3D measurements. Finally, this study seeks
to define reliability and reproducibility rather than to
validate the agreement or the diagnostic accuracy of EF and
volume measurements against an external reference stan-
dard. The accuracy of 2D and 3D methods has been
well-described (7).
Conclusions
The results of this study confirm that the 95% CI for 2D EF
(approximately 0.10 variability) is analogous to the 0.10
change in EF that defines cardiotoxicity in asymptomatic
patients (2). That noncontrast 3D EF measurements have
lower temporal variability suggesting that this approach
should be considered in patients with good acoustic win-
dows. To achieve this degree of temporal variability with
3DE, an automated or semi-automated endocardial con-
touring method should be used. Although these data are
based on patients receiving chemotherapy, our findings have
broader implications for patients in whom clinical decisions
or prognostic markers are based on changes in EF and
ventricular volumes, including patients with valvular dis-
eases, heart failure, and those undergoing surgical or percu-
taneous revascularization.
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